Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

Summary

The purpose of this study is to assess the safety and tolerability of XmAb®819 administered intravenous (IV) or subcutaneous (SC) in subjects with relapsed or refractory clear cell renal cell carcinoma and to identify the minimum safe and biologically active dose and the recommended dose (RD).

Timeline

Start

2022-06-13

Primary completion

2027-02

Completion

2028-12

Drugs

Indications